Abstract:Physiological aging or DNA‐damaging agents increase expression of p16Ink4a and p21Cip1 expression and SA‐β‐Gal cell activity in osteoblasts, while simultaneously decreasing miR‐19a‐3p expression. Restoring miR‐19a‐3p expression using a miR‐19a‐3p mimic attenuates both p16Ink4a and p21Cip1 expression, as well as SA‐β‐Gal cell activity, in senescent osteoblasts. Aging is a major risk factor for most chronic diseases, including osteoporosis, and is characterized by an accumulation of senescent cells in various tissues. MicroRNAs (miRNAs) are critical regulators of bone aging and cellular senescence. Here, we report that miR‐19a‐3p decreases with age in bone samples from mice as well as in posterior iliac crest bone biopsies of younger versus older healthy women. miR‐19a‐3p also decreased in mouse bone marrow stromal cells following induction of senescence using etoposide, H2O2, or serial passaging. To explore the transcriptomic effects of miR‐19a‐3p, we performed RNA sequencing of mouse calvarial osteoblasts transfected with control or miR‐19a‐3p mimics and found that miR‐19a‐3p overexpression significantly altered the expression of various senescence, senescence‐associated secretory phenotype‐related, and proliferation genes. Specifically, miR‐19a‐3p overexpression in nonsenescent osteoblasts significantly suppressed p16Ink4a and p21Cip1 gene expression and increased their proliferative capacity. Finally, we established a novel senotherapeutic role for this miRNA by treating miR‐19a‐3p expressing cells with H2O2 to induce senescence. Interestingly, these cells exhibited lower p16Ink4a and p21Cip1 expression, increased proliferation‐related gene expression, and reduced SA‐β‐Gal+ cells. Our results thus establish that miR‐19a‐3p is a senescence‐associated miRNA that decreases with age in mouse and human bones and is a potential senotherapeutic target for age‐related bone loss. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

A decrease in NAD+ contributes to the loss of osteoprogenitors and bone mass with aging

DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age

Nicotinamide phosphoribosyltransferase (Nampt) affects the lineage fate determination of mesenchymal stem cells: a possible cause for reduced osteogenesis and increased adipogenesis in older individuals.

Loss of Notch signaling in skeletal stem cells enhances bone formation with aging

FOXO1 differentially regulates bone formation in young and aged mice

FoxO1/NLRP3 Inflammasome Promotes Age-Related Alveolar Bone Resorption

Nicotinamide Mononucleotide Promotes Osteogenesis and Reduces Adipogenesis by Regulating Mesenchymal Stromal Cells Via the SIRT1 Pathway in Aged Bone Marrow

Osteocyte RANKL is required for cortical bone loss with age and is induced by senescence

Decreased osteogenesis in mesenchymal stem cells derived from the aged mouse is associated with enhanced NF-κB activity

Sirt1 is Involved in Decreased Bone Formation in Aged Apolipoprotein E-deficient Mice

Age-related accumulation of advanced oxidation protein products promotes osteoclastogenesis through disruption of redox homeostasis

Age-related changes in the osteogenic differentiation potential of mouse bone marrow stromal cells.

Osteoblast lineage Sod2 deficiency leads to an osteoporosis-like phenotype in mice

MicroRNA‐19a‐3p Decreases with Age in Mice and Humans and Inhibits Osteoblast Senescence

NAP1L2 drives mesenchymal stem cell senescence and suppresses osteogenic differentiation

Rejuvenating aged osteoprogenitors for bone repair

Cellular senescence as a key factor in osteoporosis: the role of SIRT1

Degeneration of the osteocyte network in the C57BL/6 mouse model of aging

Targeting NAMPT‐OPA1 for treatment of senile osteoporosis

Loss of Rictor with Aging in Osteoblasts Promotes Age-Related Bone Loss

Nicotinamide Mononucleotide Alleviates Osteoblast Senescence Induction and Promotes Bone Healing in Osteoporotic Mice